Humacyte Net Income from 2010 to 2025

HUMAW Stock  USD 0.91  0.01  1.11%   
Humacyte Net Loss yearly trend continues to be fairly stable with very little volatility. Net Loss is likely to outpace its year average in 2025. During the period from 2010 to 2025, Humacyte Net Loss regression line of quarterly data had mean square error of 2760.8 T and geometric mean of  83,745,531. View All Fundamentals
 
Net Loss  
First Reported
2010-12-31
Previous Quarter
-127.4 M
Current Value
-121 M
Quarterly Volatility
51.2 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Humacyte financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Humacyte's main balance sheet or income statement drivers, such as Depreciation And Amortization of 8.7 M, Interest Expense of 1.2 M or Selling General Administrative of 21.1 M, as well as many indicators such as Price To Sales Ratio of 96.95, Dividend Yield of 0.0 or PTB Ratio of 20.49. Humacyte financial statements analysis is a perfect complement when working with Humacyte Valuation or Volatility modules.
  
Check out the analysis of Humacyte Correlation against competitors.
For more information on how to buy Humacyte Stock please use our How to Invest in Humacyte guide.

Latest Humacyte's Net Income Growth Pattern

Below is the plot of the Net Income of Humacyte over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Humacyte financial statement analysis. It represents the amount of money remaining after all of Humacyte operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Humacyte's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Humacyte's overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported (110.78 M)10 Years Trend
Pretty Stable
   Net Income   
       Timeline  

Humacyte Net Income Regression Statistics

Arithmetic Mean(73,773,886)
Geometric Mean83,745,531
Coefficient Of Variation(69.37)
Mean Deviation31,793,832
Median(85,422,000)
Standard Deviation51,179,914
Sample Variance2619.4T
Range191.6M
R-Value0.13
Mean Square Error2760.8T
R-Squared0.02
Significance0.64
Slope1,371,227
Total Sum of Squares39290.8T

Humacyte Net Income History

2025-121 M
2024-127.4 M
2023-110.8 M
202264.2 M
202137.5 M
2020-68.7 M

Other Fundumenentals of Humacyte

Humacyte Net Income component correlations

About Humacyte Financial Statements

Humacyte investors use historical fundamental indicators, such as Humacyte's Net Income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Humacyte. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Loss-127.4 M-133.8 M
Net Loss-80.5 M-76.4 M
Net Loss(0.96)(1.01)
Net Loss(6.17)(5.86)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Humacyte Stock Analysis

When running Humacyte's price analysis, check to measure Humacyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Humacyte is operating at the current time. Most of Humacyte's value examination focuses on studying past and present price action to predict the probability of Humacyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Humacyte's price. Additionally, you may evaluate how the addition of Humacyte to your portfolios can decrease your overall portfolio volatility.